FLT3 and acute myeloid leukemia: FLT3 is most studied for its recurring mutations in AML, where the mutations causing internal tandem duplication (ITD) in the juxtamembrane domain (JD) account for about 20% of AML and about 5–10% of cases harbor point mutations in the tyrosine kinase domain (TKD).